Literature DB >> 8894574

Imipenem therapy of brain abscesses.

V Asensi1, J A Carton, J A Maradona, J M Asensi, F Pérez, P Redondo, A López, J M Arribas.   

Abstract

The efficacy of imipenem versus standard chemotherapy (both in addition to neurosurgery) in the treatment of brain abscess was compared in a retrospective study. Cure was obtained in 52 of 60 (86.7%) patients in the standard group, and in 15 of 15 (including 5 patients with multiple brain abscesses) in the imipenem group. Cure without neurosurgery was observed in 2 of 60 (3.3%) and 3 of 15 (20%) of the cases, respectively (p = 0.08). Levels of imipenem in blood, cerebrospinal fluid, and brain pus were above the minimum inhibitory concentrations of most of the abscess isolates. Side effects of imipenem were rare and tolerance was excellent. Imipenem monotherapy (3-4 g/day) for five weeks seems a reasonable therapeutic choice for treatment of bacterial brain abscesses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894574     DOI: 10.1007/bf01691152

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Brain abscess: a review of recent experience.

Authors:  N S Brewer; C S MacCarty; W E Wellman
Journal:  Ann Intern Med       Date:  1975-04       Impact factor: 25.391

2.  Brain abscess. A study of 45 consecutive cases.

Authors:  C H Chun; J D Johnson; M Hofstetter; M J Raff
Journal:  Medicine (Baltimore)       Date:  1986-11       Impact factor: 1.889

Review 3.  Bacterial brain abscesses: factors influencing mortality and sequelae.

Authors:  C Seydoux; P Francioli
Journal:  Clin Infect Dis       Date:  1992-09       Impact factor: 9.079

4.  Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system.

Authors:  S L Pestotnik; D C Classen; R S Evans; L E Stevens; J P Burke
Journal:  Ann Pharmacother       Date:  1993-04       Impact factor: 3.154

5.  Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.

Authors:  J Birnbaum; F M Kahan; H Kropp; J S MacDonald
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

6.  Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin.

Authors:  G Calandra; E Lydick; J Carrigan; L Weiss; H Guess
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

7.  Successful treatment of multiple brain abscesses with antibiotics alone.

Authors:  W H Boom; C U Tuazon
Journal:  Rev Infect Dis       Date:  1985 Mar-Apr

8.  Brain abscess: a review of 400 cases.

Authors:  S Y Yang
Journal:  J Neurosurg       Date:  1981-11       Impact factor: 5.115

9.  Successful treatment of recurrent cerebral empyema and brain abscesses with imipenem.

Authors:  J A Carton; F Perez; J A Maradona; F J Mendez
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

Review 10.  Antibacterial activity of imipenem: the first thienamycin antibiotic.

Authors:  H Kropp; L Gerckens; J G Sundelof; F M Kahan
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug
View more
  4 in total

Review 1.  Diagnosis and management of brain abscess and subdural empyema.

Authors:  Gary L Bernardini
Journal:  Curr Neurol Neurosci Rep       Date:  2004-11       Impact factor: 5.081

2.  Brain abscess associated with multidrug-resistant Capnocytophaga ochracea infection.

Authors:  Hua-Kung Wang; Yee-Chun Chen; Lee-Jene Teng; Chien-Ching Hung; Mei-Lin Chen; Shin-Hei Du; Hui-Ju Pan; Po-Ren Hsueh; Shan-Chwen Chang
Journal:  J Clin Microbiol       Date:  2006-11-29       Impact factor: 5.948

Review 3.  Brain abscess: Current management.

Authors:  Hernando Alvis Miranda; Sandra Milena Castellar-Leones; Mohammed Awad Elzain; Luis Rafael Moscote-Salazar
Journal:  J Neurosci Rural Pract       Date:  2013-08

4.  Inflammatory index and treatment of brain abscess.

Authors:  Hirofumi Oyama; Akira Kito; Hideki Maki; Kenichi Hattori; Tomoyuki Noda; Kentaro Wada
Journal:  Nagoya J Med Sci       Date:  2012-08       Impact factor: 1.131

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.